Skip to main content

Advertisement

Table 1 CKD stage definition and summary overall and by randomized treatment group per clinical trial*

From: Effect of pegloticase on renal function in patients with chronic kidney disease: a post hoc subgroup analysis of 2 randomized, placebo-controlled, phase 3 clinical trials

   Study CO405 (%) Study CO406 (%)
CKD stage eGFR definition PGL q2wks PGL q4wks Placebo Overall PGL q2wks PGL q4wks Placebo Overall
   (n = 43) (n = 41) (n = 20) (n = 104) (n = 42) (n = 43) (n = 23) (n = 108)
1 ≥90 8 (18.6) 6 (14.6) 3 (15.0) 17 (16.3) 9 (21.4) 5 (11.6) 3 (13.0) 17 (15.7)
2 60-89 14 (32.6) 12 (29.3) 4 (20.0) 30 (28.8) 12 (28.6) 19 (44.2) 13 (56.5) 44 (40.7)
3 30-59 15 (34.9) 19 (46.3) 11 (55.0) 45 (43.3) 17 (40.5) 13 (30.2) 5 (21.7) 35 (32.4)
4 15-29 6 (14.0) 4 (9.8) 2 (10.0) 12 (11.5) 4 (9.5) 5 (11.6) 2 (8.7) 11 (10.2)
5 <15 (or dialysis) 0 0 0 0 0 0 0 0
  1. CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate; PGL, pegloticase; q2wks, every 2 weeks; q4wks, every 4 weeks.
  2. *Based on the intent to treat analysis data set; that is, all randomized patients who received at least one dose of treatment.
  3. As described by the National Kidney Foundation Kidney Disease Outcomes Quality Initiative.